References
- Andre, P., Delaney, S.M., LaRocca, T., Vincent, D., DeGuzman, F., Jurek, M., Koller, B., Phillips, D.R. and Conley, P.B. (2003). P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J. Clin. Invest., 112, 398-406. https://doi.org/10.1172/JCI17864
- Birney, E., Bateman, A., Clamp, M.E. and Hubbard, T.J. (2001). Mining the draft human genome. Nature, 409, 827-828. https://doi.org/10.1038/35057004
- Caldwell, G.W., Ritchie, D.M., Masucci, J.A., Hageman, W. and Yan, Z. (2001). The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr. Top. Med. Chem., 1, 353-366. https://doi.org/10.2174/1568026013394949
- Chan, K. and Kan, Y.W. (1999). Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. USA, 96, 12731-12736. https://doi.org/10.1073/pnas.96.22.12731
- Cheng, X. and Klaassen, C.D. (2008a). Critical role of PPARalpha in perfluorooctanoic acid- and perfluorodecanoic acidinduced downregulation of Oatp uptake transporters in mouse livers. Toxicol. Sci., 106, 37-45. https://doi.org/10.1093/toxsci/kfn161
- Cheng, X. and Klaassen, C.D. (2008b). Perfluorocarboxylic acids induce cytochrome P450 enzymes in mouse liver through activation of PPAR-alpha and CAR transcription factors. Toxicol. Sci., 106, 29-36. https://doi.org/10.1093/toxsci/kfn147
- Collins, F.S. and McKusick, V.A. (2001). Implications of the Human Genome Project for medical science. JAMA, 285, 540-544. https://doi.org/10.1001/jama.285.5.540
- Cui, Y.J., Aleksunes, L.M., Tanaka, Y., Goedken, M.J. and Klaassen, C.D. (2009). Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol. Sci., 110, 47-60. https://doi.org/10.1093/toxsci/kfp094
- Debouck, C. and Metcalf, B. (2000). The impact of genomics on drug discovery. Annu. Rev. Pharmacol. Toxicol., 40, 193-207. https://doi.org/10.1146/annurev.pharmtox.40.1.193
- Descotes, J. and Testud, F. (2005). Toxicovigilance: a new approach for the hazard identification and risk assessment of toxicants in human beings. Toxicol. Appl. Pharmacol., 207, 599-603. https://doi.org/10.1016/j.taap.2005.02.019
- DiMasi, J.A., Hansen, R.W., Grabowski, H.G. and Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. J. Health. Econ., 10, 107-142. https://doi.org/10.1016/0167-6296(91)90001-4
- DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003). The price of innovation: new estimates of drug development costs. J. Health. Econ., 22, 151-185. https://doi.org/10.1016/S0167-6296(02)00126-1
- Druker, B.J. and Lydon, N.B. (2000). Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest., 105, 3-7. https://doi.org/10.1172/JCI9083
- Enomoto, A., Itoh, K., Nagayoshi, E., Haruta, J., Kimura, T., O'Connor, T., Harada, T. and Yamamoto, M. (2001). High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci., 59, 169-177. https://doi.org/10.1093/toxsci/59.1.169
- Faiola, B., Falls, J.G., Peterson, R.A., Bordelon, N.R., Brodie, T.A., Cummings, C.A., Romach, E.H. and Miller, R.T. (2008). PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol. Sci., 105, 384-394. https://doi.org/10.1093/toxsci/kfn130
- Feher, M. and Schmidt, J.M. (2003). Property distributions: differences between drugs, natural products, andmolecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci., 43, 218-227. https://doi.org/10.1021/ci0200467
- Fricker, J. (2008). Time for reform in the drug-development process. Lancet. Oncol., 9, 1125-1126. https://doi.org/10.1016/S1470-2045(08)70297-3
- Fuchs, H., Tillement, J.P., Urien, S., Greischel, A. and Roth, W. (2009). Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J. Pharm. Pharmacol., 61, 55-62. https://doi.org/10.1211/jpp.61.01.0008
- Graham, M.J. and Lake, B.G. (2008). Induction of drug metabolism: species differences and toxicological relevance. Toxicology, 254, 184-191. https://doi.org/10.1016/j.tox.2008.09.002
- Grieshaber, C.K. and Marsoni, S. (1986). Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat. Rep., 70, 65-72.
- Hernando, E., Charytonowicz, E., Dudas, M.E., Menendez, S., Matushansky, I., Mills, J., Socci, N.D., Behrendt, N., Ma, L., Maki, R.G., Pandolfi, P.P. and Cordon-Cardo, C. (2007). The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med., 13, 748-753. https://doi.org/10.1038/nm1560
- Ito, Y., Oyunzul, L., Yoshida, A., Fujino, T., Noguchi, Y., Yuyama, H., Ohtake, A., Suzuki, M., Sasamata, M., Matsui, M. and Yamada, S. (2009). Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur. J. Pharmacol., 615, 201-206. https://doi.org/10.1016/j.ejphar.2009.04.068
- Jin, D.K., Shido, K., Kopp, H.G., Petit, I., Shmelkov, S.V., Young, L.M., Hooper, A.T., Amano, H., Avecilla, S.T., Heissig, B., Hattori, K., Zhang, F., Hicklin, D.J., Wu, Y., Zhu, Z., Dunn, A., Salari, H., Werb, Z., Hackett, N.R., Crystal, R.G., Lyden, D. and Rafii, S. (2006). Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat. Med., 12, 557-567. https://doi.org/10.1038/nm1400
- Kirn, D.H. and McCormick, F. (1996). Replicating viruses as selective cancer therapeutics. Mol. Med. Today, 2, 519-527. https://doi.org/10.1016/S1357-4310(97)81456-6
- Kirschbaum, K.M., Henken, S., Hiemke, C. and Schmitt, U. (2008). Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res., 188, 298-303. https://doi.org/10.1016/j.bbr.2007.11.009
- Kubo, K., Nishikawa, K., Hardy-Yamada, M., Ishizeki, J., Yanagawa, Y. and Saito, S. (2009). Altered responses to propofol, but not ketamine, in mice deficient in the 65-kilodalton isoform of glutamate decarboxylase. J. Pharmacol. Exp. Ther., 329, 592-599. https://doi.org/10.1124/jpet.109.151456
- Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 46, 3-26. https://doi.org/10.1016/S0169-409X(00)00129-0
- Lord, P.G., Nie, A. and McMillian, M. (2006). The evolution of gene expression studies in drug safety assessment. Toxicol. Mech. Methods, 16, 51-58. https://doi.org/10.1080/15376520600558200
- Maher, J.M., Aleksunes, L.M., Dieter, M.Z., Tanaka, Y., Peters, J.M., Manautou, J.E. and Klaassen, C.D. (2008). Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol. Sci., 106, 319-328. https://doi.org/10.1093/toxsci/kfn177
- Marsh, S. (2007). Impact of pharmacogenomics on clinical practice in oncology. Mol. Diagn. Ther., 11, 79-82. https://doi.org/10.1007/BF03256226
- McCarthy, T.C., Pollak, P.T., Hanniman, E.A. and Sinal, C.J. (2004). Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator- activated receptor-alpha target gene activation. J. Pharmacol. Exp. Ther., 311, 864-873. https://doi.org/10.1124/jpet.104.072785
- McKinnon, R.A. and Nebert, D.W. (1998). Cytochrome P450 knockout mice: new toxicological models. Clin. Exp. Pharmacol. Physiol., 25, 783-787. https://doi.org/10.1111/j.1440-1681.1998.tb02153.x
- Muller, U., Steinhoff, U., Reis, L.F., Hemmi, S., Pavlovic, J., Zinkernagel, R.M. and Aguet, M. (1994). Functional role of type I and type II interferons in antiviral defense. Science, 264, 1918-1921. https://doi.org/10.1126/science.8009221
- Nebeker, J.R., Barach, P. and Samore, M.H. (2004). Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann. Intern. Med., 140, 795-801. https://doi.org/10.7326/0003-4819-140-10-200405180-00017
- Ohlstein, E.H., Ruffolo, R.R. Jr and Elliott, J.D. (2000). Drug discovery in the next millennium. Annu. Rev. Pharmacol. Toxicol., 40, 177-191. https://doi.org/10.1146/annurev.pharmtox.40.1.177
- O'Quigley, J., Pepe, M. and Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46, 33-48. https://doi.org/10.2307/2531628
- Paul, J., Seib, R. and Prescott, T. (2005). The Internet and clinical trials: background, online resources, examples and issues. J. Med. Internet. Res., 7, e5. https://doi.org/10.2196/jmir.7.1.e5
- Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. and Smith, P.G. (1976). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer., 34, 585-612. https://doi.org/10.1038/bjc.1976.220
- Phillips, J.M. and Goodman, J.I. (2009). Multiple genes exhibit phenobarbital-induced constitutive active/androstane receptormediated DNA methylation changes during liver tumorigenesis and in liver tumors. Toxicol. Sci., 108, 273-289. https://doi.org/10.1093/toxsci/kfp031
- Pineau, I., Sun, L., Bastien, D. and Lacroix, S. (2009). Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain. Behav. Immun., [Epub ahead of print].
- Pussard, E., Merzouk, M. and Barennes, H. (2007). Increased uptake of quinine into the brain by inhibition of P-glycoprotein. Eur. J. Pharm. Sci., 32, 123-127. https://doi.org/10.1016/j.ejps.2007.06.007
- Pusztai, L. (2007). Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pharmacogenomics, 8, 1443-1448. https://doi.org/10.2217/14622416.8.10.1443
- Ramos-Gomez, M., Kwak, M.K., Dolan, P.M., Itoh, K., Yamamoto, M., Talalay, P. and Kensler, T.W. (2001). Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA, 98, 3410-3415. https://doi.org/10.1073/pnas.051618798
- Reisman, S.A., Csanaky, I.L., Aleksunes, L.M. and Klaassen, C.D. (2009a). Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice. Toxicol. Sci., 109, 31-40. https://doi.org/10.1093/toxsci/kfp047
- Reisman, S.A., Csanaky, I.L., Yeager, R.L. and Klaassen, C.D. (2009b). Nrf2 activation enhances biliary excretion of sulfobromophthalein by inducing glutathione-S-transferase activity. Toxicol. Sci., 109, 24-30. https://doi.org/10.1093/toxsci/kfp045
- Reisman, S.A., Yeager, R.L., Yamamoto, M. and Klaassen, C.D. (2009c). Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol. Sci., 108, 35-47. https://doi.org/10.1093/toxsci/kfn267
- Rioux, P.P. (2000). Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am. J. Health Syst. Pharm., 57, 887-898.
- Ryan, T.P., Stevens, J.L. and Thomas, C.E. (2008). Strategic applications of toxicogenomics in early drug discovery. Curr. Opin. Pharmacol., 8, 654-660. https://doi.org/10.1016/j.coph.2008.07.011
- Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials., 10, 1-10. https://doi.org/10.1016/0197-2456(89)90015-9
- Stewart, J.J., Allison, P.N. and Johnson, R.S. (2001). Putting a price on biotechnology. Nat. Biotechnol., 19, 813-817. https://doi.org/10.1038/nbt0901-813
- Tanaka, Y., Aleksunes, L.M., Cui, Y.J. and Klaassen, C.D. (2009). ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. Toxicol. Sci., 108, 247-257. https://doi.org/10.1093/toxsci/kfp020
- Thomas, K.R. and Capecchi, M.R. (1987). Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell, 51, 503-512. https://doi.org/10.1016/0092-8674(87)90646-5
- Ulrich, R. and Friend, S.H. (2002). Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat. Rev. Drug Discov., 1, 84-88. https://doi.org/10.1038/nrd710
- Valenta, R. (2002). The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol., 2, 446-453. https://doi.org/10.1038/nri824
- Wang, S., Sim, T.B., Kim, Y.S. and Chang, Y.T. (2004). Tools for target identification and validation. Curr. Opin. Chem. Biol., 8, 371-377. https://doi.org/10.1016/j.cbpa.2004.06.001
- Weinshilboum, R. (2003). Inheritance and drug response. N. Engl. J. Med., 348, 529-537. https://doi.org/10.1056/NEJMra020021
- Woodcock, J. and Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med., 59, 1-12. https://doi.org/10.1146/annurev.med.59.090506.155819
- Yoshizato, K. and Tateno, C. (2009). A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans. PPAR Res., 2009, 476217.